Gut microbiota dysbiosis in Irritable Bowel Syndrome with Diarrhea (IBS-D gut dysbiosis)

Gut microbial community dysbiosis in Irritable Bowel Syndrome with Diarrhea (IBS-D) represents a pathological shift in the intestinal ecosystem characterized by reduced microbial diversity and an overrepresentation of pro-inflammatory taxa (NIH, 2023). This imbalance leads to metabolic dysfunction, particularly in the processing of bile acids and the production of short-chain fatty acids, which directly impacts intestinal motility and epithelial barrier integrity (PubMed, 2022). These microbial changes are linked to the activation of the mucosal immune system and the sensitization of visceral afferent nerves, contributing to the hallmark symptoms of chronic diarrhea and abdominal pain (Journal of Clinical Medicine, 2021). Therapeutic interventions, such as the non-systemic antibiotic rifaximin or targeted probiotics, aim to reshape the microbial landscape to restore metabolic homeostasis (FDA, 2015). Understanding this complex interaction is crucial for developing precision therapies that move beyond symptom management to address the underlying biological drivers of IBS-D.

Other names

Gut microbiome imbalance in IBS-DIntestinal dysbiosis in IBS-DAltered gut microbiota in IBS-DMicrobial metabolic dysfunction in IBS-D

Modulation of microbial composition to restore eubiosis, reduction of pro-inflammatory bacterial metabolites, and regulation of bile acid signaling and short-chain fatty acid production (PubMed, 2022).